Rapid rituximab administration: Safety of 60-minute infusions in malignant and benign haematological disease.
Rebecca WhitingJeanie MiskoMatthew McGuireEmma FoxPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
In the absence of severe reactions to initial and second doses, administration of rituximab over 60 min is well tolerated in patients with malignant and benign haematological disease.